Introduction
As this issue attests, the Rel/NF-kB transcription factors comprise one of the most highly-studied groups of eukaryotic gene regulatory proteins. They control the expression of genes involved in many critical physiological responses, including immune and acute phase in¯ammatory responses, cell adhesion, dierentiation, redox metabolism, and apoptosis (reviewed in Ghosh et al., 1998; Pahl, 1999) . Vertebrate Rel/NF-kB transcription complexes can be any of a variety of homo-and heterodimers formed by the subunits p50, p52, RelA (p65), RelB and c-Rel. These complexes bind to DNA regulatory sites, called kB sites, to (generally) activate speci®c target gene expression. The target gene speci®city is thought to arise primarily from the speci®c Rel/NF-kB complexes that are in dierent cell types and the distinct kB target site binding speci®cities of dierent Rel/NF-kB complexes.
In most cell types, NF-kB (the name for p50-RelA, the most common heterodimer) is retained in the cytoplasm in an inactive form through association with any of several IkB inhibitor proteins (IkBa, p105 , p100 and Bcl-3; for review, see Whiteside and IsraeÈ l, 1997) . In response to a wide array of stimuli, many of which are involved in intercellular communication, such as proin¯ammatory molecules (Pahl, 1999) , IkB is rapidly phosphorylated, ubiquitinated, and degraded. The liberated transcription complex then translocates to the nucleus where it can modulate speci®c gene expression.
The phosphorylation and the degradation of IkBa have received great attention, as key steps for the regulation of Rel/NF-kB complexes (see Karin, 1999, this issue) . The IkBa kinase (IKK) activity resides in a high molecular weight complex containing at least two kinase subunits, IKKa and IKKb, and an associated modulator (called IKKg, NEMO, or IKKAP) . Under certain conditions, a fourth molecule, called IKAP, has also been found associated with the IKK complex, but its function is not known. The IKKs share much structural similarity and form homo-and heterodimers. After stimulation of cells by agents such as tumor necrosis factor a (TNFa) or Interleukin-1 (IL-1), the IKK complex is activated by upstream kinases through phosphorylation of speci®c serine residues in the activation domain of each IKK subunit. Among the possible upstream kinases, NIK, MEKK-1, RIP, and IRAK have been found to act dierently according to the incoming stimulus (see Karin, 1999, this issue) . The activated IKK complex can then phosphorylate IkBa on two serine residues (Ser 32 and 36 in human IkBa). Phosphorylation of IkBa by IKK signals it for ubiquitination at speci®c N-terminal lysine residues by the HOS-SCF E3 ubiquitin ligase complex (Fuchs et al., 1999) , which targets IkBa for degradation by the 26S proteasome. NF-kB is now free to enter the nucleus. However, there are alternative pathways for activation of NF-kB: for example, ultraviolet irradiation NF-kB activation does not appear to use the IKK complex, and phosphorylation of IkBa at a tyrosine residue leading to activation of NF-kB has also been reported (Imbert et al., 1996; Li and Karin, 1998) .
Therefore, several steps leading to the activation of an NF-kB target gene are regulated by protein complexes that act as homo-and heterodimers and/or by families of closely related, interacting proteins. This adds additional levels of complexity to the regulation of NF-kB activity. For example, as described above, IKKa and IKKb are active as dimers. However, they appear to have distinct physiological functions in mice in that disruption of each IKK gene leads to quite dierent phenotypes (Karin, 1999, this issue) . Furthermore, IKKa and IKKb can be activated independently by dierent upstream signals. Moreover, the IKKs are likely to phosphorylate substrates in addition to the IkBs. Similarly, the dierent IkB proteins have dierent anities for the diverse Rel/NF-kB dimers.
Thus, dierent IkB proteins (which may themselves be preferred targets of dierent IKK complexes) can indirectly regulate the expression of distinct sets of genes, which are targets of speci®c Rel/NF-kB complexes. Finally, Rel/NF-kB is a family of dimeric transcription factors, which have preferred target kB sites and, thus, have distinct sets of target genes. Therefore, the activities of all interacting proteins in the Rel/NF-kB signaling pathway are no doubt dependent on the precise nature and intensity of the upstream activating signals. These interacting levels must be considered when one wants to inhibit a given NF-kB response. Thus, there are broad-range inhibitors with a wide range of action, that act at an early step of induction. In addition, there are more speci®c inhibitors, often designed according to details of the Rel/NF-kB molecular signaling pathway (Figure 1) .
Because of the multitude of cellular and organismal processes aected by Rel/NF-kB signaling, there has been great interest in modulators of this pathway. For example, because Rel/NF-kB complexes are known to play key roles in the in¯ammatory response and in the inhibition of apoptosis (Barkett and Gilmore, 1999, this issue; Ghosh et al., 1998; Pahl, 1999, this issue) , speci®c and ecient inhibitors of Rel/NF-kB have been sought. Due to the large number of inducers of Rel/ NF-kB (Pahl, 1999, this issue) and the various levels of regulation of this pathway (Karin, 1999, this issue) , inhibitors also include a large variety of molecules that act at multiple levels.
The cascade of Rel/NF-kB signaling events provides several key steps for speci®c inhibition of NF-kB activity. That is, inhibition of Rel/NF-kB activition can occur by: (1) blocking the incoming stimulating signal at an early stage and thus blocking its general eect; (2) interfering with any step in the NF-kB activation pathway by blocking a speci®c member of the cascade; or (3) blocking NF-kB nuclear activity, that is, inhibiting its translocation to the nucleus, its binding to DNA or its interactions with the basal transcription machinery. Of course, each of these three major steps would not be susceptible to the same types of inhibitors. This review will attempt to classify the multitude of NF-kB inhibitors that have been reported and to describe their mechanisms of action.
Anti-oxidant molecules
In many, but not all cell types, NF-kB can be activated by oxidants and its induced activity can be inhibited by anti-oxidants (Li and Karin, 1999; Pahl, 1999, this issue) . However, neither the target for oxidant-induced activation nor the exact pathway used by such molecules to activate NF-kB are known. The recent discovery of numerous participants in the activation cascade triggered by TNFa (TRAFs, NIK, IKKs) may enable the identi®cation of the redox-responsive target(s). It has also been reported that various agents like TNFa, IL-1, phorbol ester (e.g., PMA), lipopolysaccharide (LPS) or ultraviolet (UV) light can induce oxidative stress as well as induce NF-kB (Siebenlist et al., 1994) . This general ®nding suggested that agents with anti-oxidant activity would also inhibit activation of NF-kB as induced by a variety of agents.
Consistent with this, many compounds such as thiol anti-oxidants (e.g., NAC, PDTC) and calcium chelators (e.g., EGTA, lacidipine) have been used to inhibit hydrogen peroxide-induced NF-kB activation. Presumably, many of these agents act by scavenging reactive oxygen intermediates (ROIs) (Sen et al., 1996b) . In addition, inhibitors of mitochondrial electron transport that suppress ROI production (like rotenone) or overexpression of enzymes that are involved in regulation of the redox state of the cell can block TNFa-induced activation of NF-kB (Manna et al., , 1999b Schulze-Ostho et al., 1993) . In most cases, the inhibitory eects of anti-oxidants on NF-kB have been shown by demonstrating reduced kB site DNA-binding activity after stimulation by a given agent, without determining the precise step in NF-kB activation that is blocked. For certain anti-oxidants (glutathione for example), NF-kB activation appears to be inhibited at an early step, in that IkBa phosphorylation and degradation are blocked (Cho et al., 1998) . However, a recent report indicated that the antioxidant NAC blocks TNFa-induced degradation of IkBa but does not aect its phosphorylation or induced IKK activity (Li and Karin, 1999) .
Therefore, all anti-oxidants may not act at the same level to inhibit NF-kB. Caeic acid phenethyl ester (CAPE) is a phenolic anti-oxidant, a structural relative of¯avovoids, which are the active components of propolis from honeybee hives. CAPE has been Figure 1 Level of action of various inhibitors of the Rel/NF-kB signal transduction pathway. Various extracellular signals can initiate a pathway that activates the IkB kinase complex (IKK), leading to the phosphorylation, ubiquitination and degradation of IkB, which allows NF-kB to enter the nucleus and regulate speci®c gene expression. Some of the inhibitors that block this pathway are shown in bold. See also the text and the indicated Tables for more details and other inhibitors that act at these speci®c points reported to have anti-tumor activity in rat and human melanoma and breast carcinoma cell lines (Grunberger et al., 1988) . CAPE can also block the ability of TNFa, phorbol esters, ceramide, okadaic acid, and hydrogen peroxide to activate NF-kB. Unlike other antioxidants, CAPE does not aect IkBa phosphorylation and degradation (Natarajan et al., 1996) . Rather, CAPE-mediated inhibition of NF-kB may involve direct and speci®c interference of DNA binding by NF-kB, and this eect on DNA binding can be reversed by reducing agents like dithiothreitol and bmercaptoethanol (Natarajan et al., 1996) . Table 1 lists the many anti-oxidant molecules that have been shown to inhibit NF-kB. It is important to remember that these molecules may function in at least two ways to block activation of NF-kB. On one hand, anti-oxidants could block the production of ROIs that lead to degradation of IkBa. On the other, DNA binding by NF-kB could be directly regulated by the redox potential of the cell; for example, at least in vitro, the oxidation state of NFkB seems important for its interaction with DNA (Yang et al., 1995) , and its DNA binding can be blocked by interaction with thiol reactive metals (Shumilla et al., 1998) . Animal models have indicated that the anti-oxidant PDTC may have clinical applications for the treatment of septic shock and certain retinal neovascular diseases, due to the ability of PDTC to block NF-kB induction (Lauzurica et al., 1999; Yoshida et al., 1999) .
Proteasome inhibitors
The last common step before NF-kB is freed from the cytoplasm is the degradation of ubiquitinated IkB by the 26S proteasome (Karin, 1999, this issue; Palombella et al., 1994) . Thus, inhibitors of the ubiquitinproteasome pathway suppress activation of NF-kB by stabilizing IkB. Proteasome inhibitors and protease inhibitors that block NF-kB activity are listed in Table  2a . The inhibitors described below can all penetrate cells and inhibit NF-kB activation in a dose-dependent manner by blocking proteasome-mediated degradation of IkB (but not its phosphorylation).
The best-characterized proteasome inhibitors are peptide aldehydes. These molecules inhibit the chymotrypsin-like activity of the proteasome complex (one of the ®ve protease activities of the eukaryotic proteasome), but with distinct eciencies. ALLnL, also called calpain inhibitor I or MG101, is a cysteine protease inhibitor, but is a less potent inhibitor of the proteasome than MG132 and MG115 (Grisham et al., 1999; Jobin et al., 1998a; Palombella et al., 1994) . Suzuki and Packer, 1993a PMC (2,2,5,7,8-pentamethyl-6 -hydroxychromane) Suzuki and Packer, 1993a Lactacystin and its synthetic precursor, b-lactone, represent a second class of inhibitors of the proteasome. These molecules irreversibly block proteasome activity by acylating a threonine residue in the active site of the mammalian proteasome subunit X (Fenteany and Shreiber, 1998; Grisham, et al., 1999) . For this reason, lactacystin is considered to be a more speci®c inhibitor of the proteasome than the aldehyde peptides.
A third class of proteasome inhibitors is comprised of boronic acid peptides (or dipeptide boronates) named PS-262, PS-402, PS-341 or PS-273, etc. These molecules were originally used as inhibitors of serine proteases, but were also found to act as proteasome Palombella et al., 1994; Grisham et al., 1999; Jobin et al., 1998a ALLnL (N-acetyl-leucinyl-leucynil-norleucynal Frantz et al., 1994; Kunz et al., 1994; Marien®eld et al., 1997; McCarey et al., 1994; Meyer et al., 1997; Wechsler et al., 1994 FK506 (Tacrolimus) Okamoto Venkataraman et al., 1995 Deoxyspergualin Tepper et al., 1995 Protease inhibitors inhibitors and to be more potent than are their aldehyde analogs (Grisham et al., 1999; Iqbal et al., 1995) . An indirect method of blocking proteasomemediated degradation of IkB is by inhibiting the ubiquitin ligase that acts on IkB. For example, Yaron et al. (1997) were able to block TNFa-induced degradation of IkBa by microinjecting phosphopeptides corresponding to the signal-dependent phosphorylation site of IkBa.
Several serine proteases inhibitors with chymotrypsin-like speci®city (DCIC, TPCK, TLCK, BTEE, APNE) are also able to block proteasome function. However, unlike other protease inhibitors, those serine protease inhibitors block IkB phosphorylation as well as degradation, suggesting that a proteolytic step could (in some cases) be necessary for IKK activation. However, it is important to note that not all serine protease inhibitors are able to inhibit induction of NFkB (D' Acquisto et al., 1998; Higuchi et al., 1995; Rossi et al., 1998) .
Blockers of IkB phosphorylation/degradation
In addition to the proteasome inhibitors, several other molecules inhibit NF-kB by maintaining a high level of IkB proteins in the cytoplasm and thereby preventing NF-kB nuclear translocation. Among these molecules, some inhibit IkBa phosphorylation and its subsequent ubiquitination, while others block IkBa degradation but their level of action is not known. Those molecules can be grouped into two classes: (1) natural molecules, that is, molecules produced by cells under speci®c conditions or synthesized by diverse organisms (plants or micro-organisms), and (2) arti®cial coumpounds, designed and produced by chemical, pharmacological or molecular biological processes. Most of the molecules mentioned here are cited in Table 2b .
Signaling molecules as blockers of IkB phosphorylation/ degradation
One class of IkB metabolism blockers includes signaling molecules such as nitric oxide (NO) (Matthews et al., 1996) , Extensively Oxidized Low Density Lipoprotein (ox-LDL) (Brand et al., 1997) , 4-hydroxynonenal (HNE) (Page et al., 1999) , estrogen (E2) (Sun et al., 1998) , and prostaglandin A (Rossi et al., 1997) . At least one of these inhibitors shows pathway-speci®c inhibition of NF-kB; HNE can inhibit LPS-, IL-1-and phorbol ester-induced activation of NF-kB, but not that induced by TNFa (Page et al., 1999) .
Several endogenous intercellular signaling molecules have anti-in¯ammatory eects that appear to act by blocking Rel/NF-kB activation. For example, IL-13 can suppress TNFa production by preventing nuclear translocation of the RelA subunit and degradation of IkBa (Manna and Aggarwal, 1998a) . IL-13 also inhibits NF-kB activation induced by LPS, okadaic acid, hydrogen peroxide, and ceramide (Manna and Aggarwal, 1998a) . Alpha-melanocyte-stimulating hormone (a-MSH) can also act as a blocker of NF-kB activation as induced by a variety of agents (Manna and Aggarwal, 1998b) .
Plant anti-in¯ammatory and anti-tumor molecules
Members of this class of IkB degradation blockers were generally selected for their anti-in¯ammatory action or anti-tumor activity, and these are represented by several molecules isolated from plants. For example, this class includes sanguinarine, emodin, and sesquiterpene lactones. Sanguinarine (pseudochelerythrine, a benzophenanthridine alkaloid) is an antitumor agent, which is known to inhibit protein kinase C. However, sanguinarine can also show speci®c eects on Rel/NF-kB signaling: that is, it can prevent phosphorylation and degradation of IkBa in response to TNFa, phorbol ester, IL-1 or okadaic acid stimulation, but not after induction of NF-kB by ceramide or hydrogen peroxide (Chaturvedi et al., 1997) . Similar to sanguinarine, emodin can inhibit a variety of kinases, including protein kinase C, c-Src, p56-lck and HER-2. Moreover, emodin can inhibit IkBa degradation after stimulation with TNFa (Kumar et al., 1998) . Based on its ability to inhibit other kinases, emodin may act directly on the IKK complex to block phosphorylation of IkBa.
Rel/NF-kB inhibitors encoded by bacteria or viruses
Several proteins encoded by micro-organisms or viruses have been shown to inhibit NF-kB, and this can either enhance their replication or contribute to their pathogenicity. The YopJ protein is a Src homology 2 (SH2) domain protein encoded by the enteropathogen Yersinia pseudotuberculosis. YopJ inhibits NF-kB activation by preventing the phosphorylation and degradation of IkBa. Consequently, eukaryotic cells infected with YopJexpressing Yersinia become impaired in NF-kB-dependent cytokine expression, which coincides with YopJdependent induction of apoptosis (Schesser et al., 1998) . Recently, YopJ has been shown to bind directly to IKKb in vitro and in vivo (Orth et al., 1999) .
The core protein of hepatitis C virus (HCV) regulates cellular growth and expression from a number of cellular promoters. Stable cell transfectants expressing the HCV core protein show suppressed TNFa-, okadaic acid-, phorbol ester-and hydrogen peroxide-induced NF-kB activation through inhibition of IkBa degradation (Shrivastava et al., 1998) . Gliotoxin, a fungal metabolite produced by Aspergillus fumigatus is lethal at relatively low concentrations, but it has also been used for its immunosuppressive eects. Gliotoxin blocks activation of NF-kB DNA, apparently by preventing IkBa degradation .
The African swine fever virus (ASFV) has found a direct way to maintain NF-kB in the cytoplasm. That is, ASFV encodes an IkB-like protein that does not have the classic serine residues that direct signalinduced phosphorylation and degradation. Thus, the ASFV-encoded IkB can interact with p65, inhibit NFkB DNA binding, kB-dependent transcription, and NF-kB activation by TNFa, IFN-g and PMA (Powell et al., 1996; Revilla, et al., 1998) .
Arti®cial blockers of IkB phosphorylation/degradation
Many arti®cial compounds have been shown to block activation of NF-kB pathway at the level of IkB phosphorylation/degradation. Two pharmacologic small molecules (BAY-117821 and BAY-117083) can inhibit TNFa-induced surface expression of ICAM-1, VCAM-1, and E-selectin (all target genes of NF-kB). Each can selectively and irreversibly block TNFainduced phosphorylation of IkBa (Pierce et al., 1997) . However, it is not known what step in NF-kB activation is blocked by BAY-117821 or BAY-117083.
Cycloepoxydon and 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene are two compounds that inhibit phorbol ester-induced NF-kB and AP-1-mediated transcription of a reporter gene (Gehrt et al., 1998) . Furthermore, in tissue culture cells, cycloepoxydon strongly reduces phorbol ester-and TNFa-induced phosphorylation and degradation of IkBa (Gehrt et al., 1998) .
Genistein and erbstatin are anti-cancer agents, which have been shown to be potent inhibitors of protein tyrosine kinase (PTK) activity. Treatment of human myeloid U937 cells, T or B cells with either inhibitor completely suppresses TNFa-induced NF-kB activation by blocking IkBa degradation and the consequent translocation of the p65 subunit without aecting p50 or c-Rel (Natarajan et al., 1998) . In addition, NF-kB activation after infection with Newcastle Disease Virus can be blocked by genistein (Umansky et al., 1996) . However, genistein and erbstatin do not block NF-kB induction in all cells. For example, in MCA-101 ®brosarcoma cells and in human alveolar epithelial A439 cells, genistein and erbstatin failed to block activation of NF-kB (Bergmann et al., 1998; Mahboubi et al., 1998) .
Down-regulation of NF-kB nuclear functions: nuclear translocation, DNA binding and transcriptional activation Direct inhibition of NF-kB-speci®c transactivation could involve blocking either nuclear translocation, DNA binding, or transactivation by NF-kB dimers. In many studies described below, these last steps of NFkB activation have been used as indicators of NF-kB inhibition (either as reduced binding in an EMSA or reduced kB site reporter gene activity), but that does not mean that an earlier step is not the direct target of the inhibitor. For example, the inhibition process could also occur by maintaining a pool of IkB proteins in the cytoplasm. As in the previous section, molecules cited below and in Table 3 belong to two major groups, depending on whether they are natural or arti®cial.
Up-regulation of IkB
A few molecules have been found to inhibit NF-kB by up-regulating IkB expression. One such molecule is the b-amyloid peptide, which is deposited in the neuritic plaques that are a characteristic feature of Alzheimer's disease (AD). b-amyloid peptide appears to show a cell type-speci®c eect on NF-kB, acting as an inhibitor in some cells and an activator in others. The constitutive NF-kB activity present in fetal rat cortical neurons decreases in a concentration-and time-dependent fashion following exposure to b-amyloid, without any corresponding decrease in RelA mRNA or protein (Bales et al., 1998) . However, both IkBa mRNA and protein are increased in these cells following treatment with b-amyloid, and this increase is likely to be responsible for the decrease in activated NF-kB. This hypothesis is supported by the ®nding that pretreatment of cortical cultures with an antisense oligonucleotide to IkBa mRNA is neuroprotective towards bamyloid toxicity. In contrast to cortical neurons, exposure of rat primary astroglial cultures to bamyloid peptide results in a concentration-and timedependent activation of NF-kB with the subsequent increased transcription of the NF-kB target genes encoding IL-1b and IL-6. These data suggest that bamyloid-induced neurotoxicity as well as astrocyte activation may be mediated by Rel/NF-kB proteins, and thus alterations in NF-kB-directed gene expression may contribute to both the neurodegeneration and in¯ammatory response which occur in AD (Bales et al., 1998) .
Among cytokines, IL-10 and IL-13 (which have powerful anti-in¯ammatory activities in vitro and in vivo) both suppress nuclear localization of NF-kB and augment IkBa mRNA expression (Ehrlich et al., 1998; Lentsch et al., 1997) . IL-11 is also able to block NF-kB activation by increasing mRNA and protein levels of IkBa and IkBb following LPS treatment of macrophages (Trepicchio and Dorner, 1998).
Inhibitors of Rel/NF-kB nuclear transport
Certain Rel/NF-kB inhibitors block nuclear transport of the transcription factor. One such approach has used cell-permeable peptides that contain the nuclear localizing sequence of p50. These peptides are thought to inhibit nuclear translocation of p50-containing dimers by saturating the nuclear import machinery responsible for their uptake (Lin et al., 1995) . An allosteric drug, o,o'-bismyristoyl thiamine disul®de (BMT), suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kB (Shoji et al., 1998) .
Inhibitors of Rel/NF-kB DNA binding and transactivation
The largest class of non-speci®ed NF-kB inhibitors aect DNA binding and kB site-dependent gene expression. However, for several of the molecules cited below and in Table 3 , inhibition of DNA binding is not necessarily meant to indicate that DNA binding per se is impaired, only that the eect of the inhibitor on NF-kB has been measured by assaying the amount of protein able to bind a kB site probe in an EMSA, as compared to control cells. Some of the inhibitors included in this section are natural products like Vascular Endothelial Growth Factor (VEGF) which is produced by almost all tumors and aects the ability of hemopoietic progenitor cells to dierentiate into dendritic cells Oyama et al., 1998) .
Some of these molecules show stimulus-dependent inhibition of NF-kB activation. For example, the bio¯avonoid silymarin potently suppresses NF-kB DNA-binding activity induced by okadaic acid or by LPS in the hepatoma cell line HepG2, but TNFainduced NF-kB activation is not aected by silymarin (Saliou et al., 1998) .
Some of these molecules have therapeutic potential. For example, the atrial natriuretic peptide (ANP) can prevent the marked augmentation of NF-kB DNAbinding activity which is associated with rat liver damage during reperfusion (Gerbes et al., 1998) . In addition, KT-90 (a synthesized morphine derivative) is an analgesic, which is ®ve times more potent than morphine. KT-90 has also been found to inhibit the growth of certain human cancer cell lines up to 80 times more potently than morphine. KT-90 inhibits TNFa gene expression induced by okadaic acid and phorbol esters, and is associated with a reduction in NF-kB DNA-binding activity (Sueoka et al., 1998) . Ribavirin and pentoxifylline, inhibitors of viral production, have been reported to block NF-kB DNA binding (Biswas et al., 1993; Fiedler et al., 1996) . Pentoxifylline is particularly interesting in that it appears to have speci®c eects on c-Rel (among Rel/ NF-kB family members) and to block c-Rel in a cell type-speci®c fashion, namely, in T cells but not in B cells (Wang et al., 1997) . Lastly, this group includes two anti-in¯ammatory neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclaseactivating polypeptide (PACAP), which can inhibit TNFa production (by blocking induction of NF-kB) in LPS-stimulated macrophages (Delgado et al., 1998) .
Several small molecules, with quite de®ned activities, have been shown to block NF-kB activity. D609, RO31-8220 and SB203580 are compounds that selectively inhibit phosphatidylcholine-phospholipase C inhibitor, protein kinase C and p38 MAPK, respectively. In the human A549 cell line, they are also able to block NF-kBdependent transcription after stimulation by IL-1 and TNFa. However, none of these molecules inhibits IkBa degradation, NF-kB nuclear translocation or DNA binding (Bergmann et al., 1998) . In another study, LY294,002 and wortmannin (both PI-3 kinase inhibitors) have been used to block IL-1-induced NF-kB activation of a reporter gene (Reddy et al., 1997; Sizemore et al., 1999) . LY294,002 could not inhibit IkBa degradation or NF-kB DNA binding, but it could block IL-1-stimulated phosphorylation of NF-kB, especially the p65/RelA subunit. Furthermore, overexpression of the p110 catalytic subunit of PI-3 kinase induces RelAmediated transactivation and LY294,002 represses this process (Sizemore et al., 1999) .
Lastly, there have been two reports suggesting that Bc1-2, an inhibitor of apoptosis, can also function as an NF-kB inhibitor. In one study (Grimm et al., 1996) , Bc1-2 suppressed transactivation by RelA without aecting the nuclear transport or DNA binding of NF-kB; whereas in a second report (Badrichani et al., 1999) , Bc1-2 blocked degradation of IkBa.
Commonly used drugs that act, at least in part, by inhibiting NF-kB activity Because many of NF-kB target genes are involved in the acute phase or in¯ammatory response, inhibition of NF-kB has been used to minimize the pathologic eects induced by the immune system misregulation. As such, several of the most commonly used drugs can inhibit NF-kB activity.
Anti-in¯ammatory drugs
One example of an anti-in¯ammatory agent that can inhibit NF-kB and whose molecular target appears to be known is aspirin or sodium salicylate (Grilli et al., 1997) . Aspirin is one of a class of nonsteroidal antiin¯ammatory drugs (NSADs) that have commonly been thought to act via inhibition of prostaglandin synthesis (Weissmann, 1991) . However, aspirin has also been shown to block NF-kB activity by preventing IkBa degradation after stimulation by phorbol ester, TNFa or LPS (Kopp and Ghosh, 1994) . Even if the speci®city of aspirin for inhibition of NF-kB has been (Frantz and O'Neill, 1995) , it is a quite eective blocker of NF-kB induction. Aspirin and sodium salicylate speci®cally inhibit NF-kB nuclear translocation by preventing IkBa phosphorylation and degradation (Pierce et al., 1996) . Recently, Yin et al. (1998) have shown that aspirin can directly bind to and inhibit the kinase activity of IKKb by reducing its ability to bind ATP. Other NSADs, such as tepoxaline, defereoxamine, and ibuprofen, are also able to inhibit NF-kB (Kazmi et al., 1995; Palayoor et al., 1998; Ritchie et al., 1995) . Of particular interest, ibuprofen has been used as a growth suppressor for human colon cancer and to sensitize prostate cancer cells to ionizing therapy (Palayoor et al., 1998) .
Glucocorticoids, such as dexametasone, prednisone and methylprednisolone, are used for their antiin¯ammatory properties and to prevent allograft rejection. Their physiological eects are, at least partially, mediated through inhibition of NF-kB. Two models have been proposed for inhibition of NF-kB by glucocorticoids. On the one hand, glucocorticoids have been shown to inhibit kB-dependent transcription by directly interacting with the NF-kB RelA subunit and aecting its transactivation potential (Brostjan et al., 1996; De Bosscher et al., 1997; Ray and Prefontaine, 1994; Simpson and Morris 1999) . On the other hand, glucocorticoids have also been shown to enhance IkBa production, leading to sustained inhibition of NF-kB (Auphan et al., 1995 , Scheinman et al., 1995 .
Immunosuppressive agents
Several well-known immunosuppressants target NFkB. Cyclosporin A (CsA), inhibits B-and T-cell proliferation by blocking the activity of calcineurin, a calcium and calmodulin-dependent serine/threonine phosphatase (Frantz et al., 1994) . Several reports have shown that CsA can also inhibit NF-kB induction, although the mechanism by which CsA exerts this inhibitory eect may dier in dierent situations. In vitro, CsA has been reported to act as a noncompetitive inhibitor of the chymotrypsin-like activity of the proteasome, enabling it to block LPS-induced IkB degradation and p105 processing in vivo (Meyer et al., 1997) . Similarly, CsA prevents NF-kB nuclear translocation in stimulated T cells (McCarey et al., 1994) by preventing the inducible degradation of IkBa and IkBb; however, in these cells, CsA does not inhibit the processing of p105 to p50 (Marienfeld et al., 1997) . CsA is able to block the activation of IL-8 gene expression by NF-kB in T cells (Wechsler et al., 1994) and it reduces NF-kB DNA binding in murine mesangial cells (Kunz et al., 1995) . Interestingly, like aspirin, CsA has also been shown to be neuroprotective (Meyer et al., 1997) .
FK506 is an immunosuppressant that acts as a potent blocker of B-and T-cell proliferation. At least in part, FK506, like CsA, acts by blocking the activity of calcineurin. However, unlike CsA, the inhibitory eect of FK506 on NF-kB appears to be speci®c for c-Rel, among the Rel/NF-kB family members. That is, FK506 can speci®cally block cRel nuclear translocation (but not p50/RelA) after treatment of cells with phorbol esters and ionomycin (Venkataraman et al., , 1996 Sen et al., 1995) . FK506 also has been reported to block NF-kB DNA binding in Jurkat T cells stimulated with phorbol ester (Okamoto et al., 1994) . Therefore, the antiproliferative eects of FK506 in T cells results from inhibition of Rel/NF-kB, which consequently blocks transcription of the IL-2 and IL-2 receptor genes by interfering with the induction of kB site-dependent transcription of their promoters (Ser¯ing et al., 1995; Venkataraman et al., 1995) .
Certain other immunosuppressants act at dierent levels than CsA and FK506 to block immune cell proliferation. For example, PG490 (pure triptolide, a diterpene triepoxide) is an immunosuppressant molecule that can synergize with CsA to inhibit transcriptional activation by NF-kB. However, PG490 does not appear to interfere with the induction of NF-kB DNA binding, suggesting that it acts to inhibit transcriptional activation by NF-kB (Qiu et al., 1999) . Morever, the immunosuppressant deoxyspergualin inhibits NFkB nuclear translocation by a mechanism involving the heat shock protein hsp70 (Tepper et al., 1995) .
Thus, it appears that dierent immunosuppressants can inhibit NF-kB by distinct mechanisms. They can inhibit NF-kB nuclear translocation by stabilizing IkBa (Meyer et al., 1997) , by inhibiting calcineurin (Frantz et al., 1994) , by binding heat shock proteins (Tepper et al., 1995) or by modulating the DNA binding or transactivation potential of NF-kB (Kunz et al., 1995; McCarey et al., 1994; Qiu et al., 1999; Wechsler et al., 1994) .
Molecular blockers of the NF-kB signaling pathway
Another general strategy for inhibiting NF-kB activity is to develop genetically-engineered proteins that block speci®c steps in the activation process. Because many of the molecular details of the NF-kB signaling pathway are now known, it has been relatively straight-forward to design constitutive inhibitors of molecules in this pathway. The eects of these polypeptide inhibitors are then determined in tissue culture cells or occasionally in transgenic mice. At this time, these types of inhibitors have not yet been used in clinical studies. In part, this is because these experimental approaches have sometimes yielded dierent results depending on the experimental approach used (transient transfection vs stable cell lines, overexpression vs knockout, etc). Nevertheless, the characterization of these types of`molecular' inhibitors may lead to development of very speci®c anti-NF-kB drugs. Below are some examples of inhibitors of NF-kB activity that have been developed based on the structure and function of members of the signaling cascade.
Tumor necrosis factor receptor-associated factors (TRAFs)
Many cytokines signal through distinct cell-surface receptors to activate transcription factor NF-kB. Members of the tumor necrosis factor receptorassociated factors (TRAF) protein family act as adaptor molecules for the activation of NF-kB by the TNF receptor superfamily (including TNFR1, TNFR2 and CD40). TRAF2 is recruited to the TNFR1 and TNFR2 receptors following TNF stimulation, and it is required for CD40-and TNFa-mediated activation of NF-kB. A TRAF2 mutant lacking its N-terminal RING ®nger domain is a dominant-negative inhibitor of TNFa-(but not IL-1) induced NF-kB activation (Hsu et al., 1996) . However, cells derived from TRAF2-de®cient mice have only a small reduction in NF-kB activation after TNFa stimulation, suggesting that TRAF2-independent pathways of NF-kB activation exist (Yeh et al., 1997) . In contrast to TRAF2, a dominant-negative mutant of TRAF6 inhibits NF-kB activation signaled by IL-1 but not by TNFa (Cao et al., 1996) , and TRAF6 appears to participate exclusively in the IL-1 signal transduction pathway by interacting with the IL-1 receptor and NIK.
I-TRAF is a TRAF-interacting protein that binds to the conserved TRAF-C domain of the TRAF1, TRAF2, and TRAF3. Overexpression of I-TRAF inhibits TRAF2-mediated NF-kB activation as signaled by CD40 and both TNF receptors. Thus, I-TRAF appears to act as a natural inhibitor of TRAF function (Rothe et al., 1996) .
NIK and MEKK1
Two kinases that can lead to activation of the IKK complex are NIK and MEKK1. Overexpression of NIK potently induces NF-kB (Malinin et al., 1997) , and MEKK1 is activated by TNFa and IL-1 and can potentiate the stimulatory eect of TNFa on IKK and NF-kB activation (Hirano et al., 1996; Lee et al., 1998) .
NIK has also been reported to interact with several members of the NF-kB signaling pathway, including TRAF2, TRAF6, and IKK. In addition, NIK may directly phosphorylate members of the IKK complex. Overexpression in cells of kinase-de®cient NIK mutants not only fails to activate NF-kB, but blocks the ability of IL-1 and TNFa to induce NF-kB (Malinin et al., 1997; Song et al., 1997) . However, others have questioned the involvement of NIK in activation of NF-kB by IL-1 and TNFa (Baud et al., 1999) , and NIK-de®cient mice, despite dying at an early embryonic stage, still show activation of NF-kB after IL-1 and TNFa stimulation (D Goeddel, personal communication) .
When overexpressed, MEKK1 stimulates the activities of both IKKa and IKKb in transfected HeLa cells and directly phosphorylates the IKKs in vitro (Lee et al., 1998) . Furthermore, MEKK1 may act in parallel to NIK, leading to synergistic activation of the IKK complex (Nemoto et al., 1998) , and a dominantnegative mutant of MEKK1 partially blocks activation of the IKK complex by TNFa (Hirano et al., 1996; Lee et al., 1997) . However, the physiological relevance of activation of IKK and NF-kB by overexpressed MEKK1 has been questioned (Karin and Delhase, 1998) .
IKK complex mutants
A high molecular weight complex containing IKKa and IKKb is directly responsible for the induced phosphorylation of IkBa, and overexpression of dominant-negative mutants of IKK can block activation of NF-kB (Karin, 1999, this issue) . However, the two IKKs seem to have dierent functions in the cell and their dominant-negative mutants do not always behave identically. Dominant-negative mutations in the kinase domain of either IKK suppress IL-1 and TNFa induction of NF-kB, but IKKb mutants always have more dramatic eects, and other results suggest that TNFa and IL-1 primarily activate IKK through IKKb (Karin, 1999, this issue) . Dominant-negative forms of the IKKs, which are capable of blocking activation of NF-kB, can be created either by mutations in the ATPbinding site or by mutations in the kinase activation loop (DiDonato et al., 1997; Ling et al., 1998; Mercurio et al., 1997; Regnier et al., 1997; Woronicz et al., 1997; Zandi et al., 1997) .
Dominant-negative IKK mutants can show stimulus-dependent inhibition. For example, overexpression of wild-type IKKa, wild-type IKKb or a dominantnegative mutant IKKa does not aect LPS-induced kB-dependent transcription in THP-1 monocytic cells, whereas a dominant-negative mutant of IKKb does inhibit LPS induction of kB site-dependent transcription (O'Connell et al., 1998) .
The analysis of IKK knockout mice again points out the need for caution in interpreting tissue culture experiments wherein proteins are grossly overexpressed. First, mice with knockouts of IKKa versus IKKb have quite dierent phenotypes: when the gene encoding IKKa is disrupted, mice die shortly after birth with blocked limb emergence due to abnormal keratinocyte function, whereas IKKb-de®cient mice die between embryonic day 12.5 and day 14 with extensive liver damage due to apoptosis (similar to the phenotype observed in mice lacking RelA) (Karin, 1999, this issue) . Furthermore, IkBa degradation and NF-kB induction are not impaired after induction by TNFa or IL-1 in cells from IKKa-de®cient mice, however, TNFa-and IL-1-induced degradation of IkBa and NF-kB activation are abrogated in cells from IKKb-de®cent mice. Thus, most tissue culture experiments that have looked at IKK activation have focused on signaling through IKKb.
IKKg is a member of the IKK complex and is required for kinase activation. IKKg plays a crucial role in NF-kB activation by IKK since cells that do not express IKKg do not show induced NF-kB activity in response to various stimuli (Yamaoka et al., 1998) . Moreover, cells lacking IKKg cannot be transformed by the Tax oncoprotein of HTLV-1, suggesting that IKKg could be a target for anti-HTLV-1 therapies.
IkBa super-repressor
Blocking nuclear transport of NF-kB can also be accomplished by imprisoning it in the cytoplasm in a manner such that it cannot respond to an activation signal. This has been achieved by using mutant forms of IkBa, called super-repressors, which cannot be phosphorylated or degraded. These superrepressor IkB's carry mutations of the signal-induced phosphorylation sites Ser 32 and 36 (wherein alanine residues replace the 2 serines), of the lysine ubiquitination sites (Lys-4Arg mutations) or are deleted for their ®rst 40 amino acids and thus, can be neither phosphorylated nor ubiquitinated. In addition, speci®c C-terminal Ser to Ala mutations are sometimes included to reduce the constitutive turnover of IkBa (van Antwerp et al., 1996) . Because these super-repressor forms of IkBa can still interact with NF-kB dimers, they are very potent inhibitors of its activity by keeping it permanently in the cytoplasm (Bentires-Alj et al., 1999; Jobin et al., 1998b; van Antwerp et al., 1996; Wang et al., 1996) . Such molecules have been used succesfully to inhibit NF-kB activity and to study its role in development (Bushdid et al., 1998; Kanegae et al., 1998) or to sensitize cells to apoptosisinducing agents (van Antwerp et al., 1996; Wang et al., 1996) .
Recently, inhibition of NF-kB through expression of an IkBa super-repressor has been used to sensitize chemoresistant tumors to apoptosis induced by TNFa and the chemotherapeutic compound CPT-11, resulting in tumor regression (Wang et al., 1999) , and also to inhibit the growth of human head and neck carcinoma cells in vitro and in vivo (Duey et al., 1999) . But again, such results must be taken with caution, in that overexpression of the IkBa super-repressor has also been associated with the spontaneous development of squamous cell carcinoma in one murine model system (van Hogerlinden et al., 1999) .
Conclusions
From the commonly-used aspirin to the IkBa super repressor, numerous inhibitors of the NF-kB activity have been described. Their mode of action is sometimes known, other times it has simply been noticed that such molecules inhibit NF-kB-induced DNA binding. Some Rel/NF-kB inhibitors are`broadrange' inhibitors, such as the many anti-oxidants and proteasome inhibitors, which can block most NF-kB activating signals. However, the broad-range inhibitors may aect a variety pathways; for example, AP-1 is also induced by oxidative stress and TNFa. Other inhibitors of NF-kB block activation when induced by only certain stimuli, for example by acting on a particular protein in the signaling cascade or by blocking speci®c Rel/NF-kB complexes. Nevertheless, even these speci®c inhibitors may block other pathways, either because their target participates in several intracellular pathways or because they block a certain class of protein. Indeed, in most of the studies described in this review, neither the molecular target in the NF-kB signaling pathway nor cell-type speci®city of the inhibitors are known. In addition, it is often not clear whether the concentrations of inhibitors used in tissue culture experiments can be applied to in vivo situations. Lastly, some inhibitors of NF-kB may have eects on other signaling pathways or cellular functions. Therefore, such inhibitors can perhaps also be used to identify new pathways used by members of the Rel/NF-kB cascade. The use of overlapping signaling pathways makes it a challenge to ®nd molecules that block speci®c pathways leading to NF-kB activation without interfering with other signaling cascades. Recent descriptions of the crystallographic structure of NF-kB dimers or NF-kB/IkB complexes will no doubt help in the design of molecules that are quite speci®c for inhibiting only Rel/NF-kB proteins. A future goal will be to discover molecules that can inhibit distinct Rel/NF-kB complexes induced by select stimuli in speci®c cell types.
